Phase 2b Multicenter, Randomized, Double-Blind, Placebo- and Active-Controlled, Parallel-Group Study to Assess the PD Response and Safety of Three Dose Levels of (PB1023) Injection Following 20 Weeks of Weekly SC Dosing in Adults With T2DM

This study has been completed.
Information provided by (Responsible Party):
PhaseBio Pharmaceuticals Inc. Identifier:
First received: July 24, 2012
Last updated: October 13, 2015
Last verified: October 2015
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: July 2013
  Primary Completion Date: July 2013 (Final data collection date for primary outcome measure)
  Certification or Request for Extension to Delay Results Received: October 28, 2014